Premium
O1‐12‐06: PHASE 1 MULTIPLE ASCENDING DOSE (MAD) STUDY OF PHOSPHODIESTERASE‐9 INHIBITOR E2027: CONFIRMATION OF TARGET ENGAGEMENT AND SELECTION OF PHASE 2 DOSE IN DEMENTIA WITH LEWY BODIES
Author(s) -
Landry Ishani,
Lai Robert YK.,
Boyd Peter,
Aluri Jagadeesh,
Chang Min-Kun,
Ino Mitsuhiro,
Horie Kanta,
Schuck Edgar L.,
Luthman Johan
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.2401
Subject(s) - tolerability , pharmacokinetics , pharmacodynamics , phosphodiesterase , cyclic guanosine monophosphate , pharmacology , medicine , dosing , phosphodiesterase inhibitor , placebo , dose–response relationship , guanosine , endocrinology , chemistry , adverse effect , pathology , biochemistry , alternative medicine , nitric oxide , enzyme
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom